New Guidelines on Cervical Cancer Screening

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> American Cancer Society Updates Guideline for Cervical Cancer Screening

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> BRAF V600–Mutated Melanoma